Liver-directed chemotherapy versus standard chemotherapy for RAS-mutated CRC
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests whether delivering chemotherapy directly into the liver (with an IV medicine added, depending on the group) works better than standard chemotherapy given through a vein. It is for people whose colorectal cancer has spread to the liver but can’t be removed by surgery yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon cancer (colorectal adenocarcinoma).
- Your scans show liver metastases that the team says are “unresectable” (not safely removable).
- Your tumor has a RAS mutation (and includes BRAF V600E mutation status as specified).
- You have not had any prior treatment specifically for the liver metastases (no liver chemotherapy, surgery, radiation, or targeted liver procedures).
- Your cancer is only in the liver (no extra spread found in the body, with a small allowance for tiny lung/lymph node spots).
- Your body tests and health status are strong enough for chemotherapy (blood counts, liver/kidney function, no major fluid buildup in the belly).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
This trial tests giving high-dose melphalan directly into the liver's blood supply, followed by standard cancer therapy, for people whose colorectal cancer has spread mainly to the liver. The goal is to see if this approach is safer and works better than standard treatment alone.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial tests a new drug (retlirafusp alfa) combined with two chemotherapy drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has spread to the liver and has a specific gene change (RAS mutation). It aims to see if this combination can shrink tumors and improve outcomes in people who have not had prior treatment.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.